A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
This study tests a medicine called cabozantinib to see how well it treats non-small cell lung cancer that has specific genetic changes. By blocking proteins that help cancer cells grow and spread, researchers hope this drug can shrink tumors and improve health outcomes.
This study is for adults with advanced non-small cell lung cancer that has spread or cannot be removed by surgery. You must also have specific genetic changes in your cancer cells, such as RET, ROS1, or NTRK fusions, or increased MET or AXL activity.
Participants will take cabozantinib, which is an oral medication taken by mouth. The medical team will monitor you closely to see how the cancer responds to the drug and to manage any side effects that may occur.
The study is currently recruiting patients at locations in Basking Ridge, Middletown, and Montvale, New Jersey. Your doctor can help you determine if one of these centers is the right fit for your care.
- 1The study uses an oral targeted therapy designed to stop cancer cells from growing and spreading.
- 2Participation depends on having specific genetic markers in your lung cancer cells.
- 3Researchers have prior experience with this drug, helping them better anticipate and manage potential side effects.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.